These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22785114)

  • 21. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Ulusoy S; Ozkan G; Orem C; Kaynar K; Koşucu P; Kiriş A
    Ren Fail; 2010; 32(8):913-7. PubMed ID: 20722556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.
    Serra AL; Kistler AD; Poster D; Struker M; Wüthrich RP; Weishaupt D; Tschirch F
    BMC Nephrol; 2007 Sep; 8():13. PubMed ID: 17868472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.
    Riegersperger M; Herkner H; Sunder-Plassmann G
    Trials; 2015 Apr; 16():182. PubMed ID: 25899445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
    Cruzado JM; Poveda R; Ibernón M; Díaz M; Fulladosa X; Carrera M; Torras J; Bestard O; Navarro I; Ballarín J; Romero R; Grinyó JM
    Nephrol Dial Transplant; 2011 Nov; 26(11):3596-602. PubMed ID: 21393611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus therapy to halt the progression of ADPKD.
    Perico N; Antiga L; Caroli A; Ruggenenti P; Fasolini G; Cafaro M; Ondei P; Rubis N; Diadei O; Gherardi G; Prandini S; Panozo A; Bravo RF; Carminati S; De Leon FR; Gaspari F; Cortinovis M; Motterlini N; Ene-Iordache B; Remuzzi A; Remuzzi G
    J Am Soc Nephrol; 2010 Jun; 21(6):1031-40. PubMed ID: 20466742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    He Q; Lin C; Ji S; Chen J
    Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
    Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M
    Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open.
    Jardine MJ; Liyanage T; Buxton E; Perkovic V
    Nephrol Dial Transplant; 2013 Feb; 28(2):242-4. PubMed ID: 23222536
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
    Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Perrone RD; Steinman TI; Torres VE;
    Curr Hypertens Rev; 2017; 13(2):109-120. PubMed ID: 28460625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycystic kidney disease: a 2011 update.
    Steinman TI
    Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):189-94. PubMed ID: 22274800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
    Tao Y; Kim J; Schrier RW; Edelstein CL
    J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD.
    Higashihara E; Nutahara K; Horie S; Muto S; Hosoya T; Hanaoka K; Tuchiya K; Kamura K; Takaichi K; Ubara Y; Itomura M; Hamazaki T
    Nephrol Dial Transplant; 2008 Sep; 23(9):2847-52. PubMed ID: 18372389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirolimus reduces polycystic liver volume in ADPKD patients.
    Qian Q; Du H; King BF; Kumar S; Dean PG; Cosio FG; Torres VE
    J Am Soc Nephrol; 2008 Mar; 19(3):631-8. PubMed ID: 18199797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease.
    Miller RH; Lehmkuhl LB; Smeak DD; DiBartola SP; Radin J
    Am J Vet Res; 1999 Dec; 60(12):1516-25. PubMed ID: 10622161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complications of autosomal dominant polycystic kidney disease in 50 haemodialysed patients. A case-control study. The U.C.L. Collaborative Group.
    Christophe JL; van Ypersele de Strihou C; Pirson Y
    Nephrol Dial Transplant; 1996 Jul; 11(7):1271-6. PubMed ID: 8672022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term impact of laparoscopic cyst decortication on renal function, hypertension and pain control in patients with autosomal dominant polycystic kidney disease.
    Haseebuddin M; Tanagho YS; Millar M; Roytman T; Chen C; Clayman RV; Miller B; Desai A; Benway B; Bhayani S; Figenshau RS
    J Urol; 2012 Oct; 188(4):1239-44. PubMed ID: 22902029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.